Israel

Israel

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
0.53 (0.43 - 0.62) 2019 Modelled IHME
0.56 (0.46 - 0.65) 2018 Modelled IHME
0.58 (0.48 - 0.68) 2017 Modelled IHME
0.58 (0.48 - 0.68) 2016 Modelled IHME
0.59 (0.48 - 0.70) 2015 Modelled IHME
0.59 (0.48 - 0.71) 2014 Modelled IHME
0.6 (0.49 - 0.72) 2013 Modelled IHME
0.62 (0.50 - 0.73) 2012 Modelled IHME
0.63 (0.51 - 0.74) 2011 Modelled IHME
0.64 (0.52 - 0.76) 2010 Modelled IHME
0.65 (0.53 - 0.77) 2009 Modelled IHME
0.66 (0.53 - 0.78) 2008 Modelled IHME
0.67 (0.54 - 0.79) 2007 Modelled IHME
0.68 (0.55 - 0.81) 2006 Modelled IHME
0.69 (0.55 - 0.83) 2005 Modelled IHME
0.71 (0.57 - 0.85) 2004 Modelled IHME
0.73 (0.59 - 0.88) 2003 Modelled IHME
0.75 (0.61 - 0.90) 2002 Modelled IHME
0.77 (0.62 - 0.93) 2001 Modelled IHME
0.78 (0.63 - 0.96) 2000 Modelled IHME
0.79 (0.64 - 0.96) 1999 Modelled IHME
0.8 (0.66 - 0.97) 1998 Modelled IHME
0.81 (0.66 - 0.98) 1997 Modelled IHME
0.81 (0.67 - 0.98) 1996 Modelled IHME
0.82 (0.66 - 0.99) 1995 Modelled IHME
0.82 (0.67 - 0.98) 1994 Modelled IHME
0.82 (0.67 - 0.98) 1993 Modelled IHME
0.82 (0.67 - 0.98) 1992 Modelled IHME
0.83 (0.67 - 0.99) 1991 Modelled IHME
0.83 (0.66 - 0.99) 1990 Modelled IHME
1.22 (0.97 - 1.53) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.04 (0.02 - 0.05) 2019 Modelled IHME
0.04 (0.02 - 0.05) 2018 Modelled IHME
0.04 (0.02 - 0.05) 2017 Modelled IHME
0.04 (0.02 - 0.05) 2016 Modelled IHME
0.04 (0.02 - 0.05) 2015 Modelled IHME
0.04 (0.02 - 0.05) 2014 Modelled IHME
0.04 (0.02 - 0.05) 2013 Modelled IHME
0.04 (0.02 - 0.05) 2012 Modelled IHME
0.04 (0.02 - 0.05) 2011 Modelled IHME
0.04 (0.02 - 0.05) 2010 Modelled IHME
0.04 (0.02 - 0.05) 2009 Modelled IHME
0.04 (0.02 - 0.05) 2008 Modelled IHME
0.04 (0.02 - 0.05) 2007 Modelled IHME
0.04 (0.02 - 0.05) 2006 Modelled IHME
0.04 (0.02 - 0.05) 2005 Modelled IHME
0.04 (0.02 - 0.05) 2004 Modelled IHME
0.04 (0.02 - 0.05) 2003 Modelled IHME
0.04 (0.02 - 0.05) 2002 Modelled IHME
0.04 (0.02 - 0.05) 2001 Modelled IHME
0.03 (0.02 - 0.05) 2000 Modelled IHME
0.07 (0.05 - 0.10) 1999 Modelled IHME
0.16 (0.10 - 0.22) 1998 Modelled IHME
0.26 (0.18 - 0.36) 1997 Modelled IHME
0.35 (0.23 - 0.48) 1996 Modelled IHME
0.39 (0.26 - 0.53) 1995 Modelled IHME
0.39 (0.26 - 0.53) 1994 Modelled IHME
0.39 (0.26 - 0.53) 1993 Modelled IHME
0.39 (0.27 - 0.52) 1992 Modelled IHME
0.39 (0.27 - 0.52) 1991 Modelled IHME
0.39 (0.26 - 0.53) 1990 Modelled IHME
0.48 (0.32 - 0.69) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
14 (10 - 20) 2019 Modelled IHME
14 (10 - 20) 2018 Modelled IHME
14 (10 - 20) 2017 Modelled IHME
14 (10 - 20) 2016 Modelled IHME
14 (10 - 20) 2015 Modelled IHME
14 (10 - 20) 2014 Modelled IHME
14 (10 - 20) 2013 Modelled IHME
14 (10 - 20) 2012 Modelled IHME
14 (10 - 20) 2011 Modelled IHME
14 (10 - 20) 2010 Modelled IHME
14 (10 - 20) 2009 Modelled IHME
15 (10 - 21) 2008 Modelled IHME
15 (11 - 21) 2007 Modelled IHME
15 (11 - 22) 2006 Modelled IHME
16 (11 - 22) 2005 Modelled IHME
15 (11 - 22) 2004 Modelled IHME
15 (11 - 22) 2003 Modelled IHME
15 (11 - 22) 2002 Modelled IHME
15 (11 - 22) 2001 Modelled IHME
15 (11 - 22) 2000 Modelled IHME
15 (11 - 22) 1999 Modelled IHME
15 (11 - 22) 1998 Modelled IHME
15 (10 - 22) 1997 Modelled IHME
15 (10 - 22) 1996 Modelled IHME
15 (10 - 22) 1995 Modelled IHME
15 (11 - 22) 1994 Modelled IHME
15 (11 - 22) 1993 Modelled IHME
15 (11 - 22) 1992 Modelled IHME
15 (11 - 22) 1991 Modelled IHME
15 (11 - 22) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
95 2018 Survey/reported WHO/UNICEF
95 2017 Survey/reported WHO/UNICEF
95 2016 Survey/reported WHO/UNICEF
96 2015 Survey/reported WHO/UNICEF
97 2014 Survey/reported WHO/UNICEF
97 2013 Survey/reported WHO/UNICEF
97 2012 Survey/reported WHO/UNICEF
98 2011 Survey/reported WHO/UNICEF
97 2010 Survey/reported WHO/UNICEF
98 2009 Survey/reported WHO/UNICEF
99 2008 Survey/reported WHO/UNICEF
99 2007 Survey/reported WHO/UNICEF
96 2006 Survey/reported WHO/UNICEF
96 2005 Survey/reported WHO/UNICEF
96 2004 Survey/reported WHO/UNICEF
96 2003 Survey/reported WHO/UNICEF
96 2002 Survey/reported WHO/UNICEF
96 2001 Survey/reported WHO/UNICEF
96 2000 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
97 2018 Survey/reported WHO/UNICEF
97 2017 Survey/reported WHO/UNICEF
95 2016 Survey/reported WHO/UNICEF
96 2015 Survey/reported WHO/UNICEF
97 2014 Survey/reported WHO/UNICEF
97 2013 Survey/reported WHO/UNICEF
97 2012 Survey/reported WHO/UNICEF
98 2011 Survey/reported WHO/UNICEF
97 2010 Survey/reported WHO/UNICEF
98 2009 Survey/reported WHO/UNICEF
99 2008 Survey/reported WHO/UNICEF
99 2007 Survey/reported WHO/UNICEF
96 2006 Survey/reported WHO/UNICEF
96 2005 Survey/reported WHO/UNICEF
99 2004 Survey/reported WHO/UNICEF
98 2003 Survey/reported WHO/UNICEF
98 2002 Survey/reported WHO/UNICEF
96 2001 Survey/reported WHO/UNICEF
98 2000 Survey/reported WHO/UNICEF
96 1999 Survey/reported WHO/UNICEF
97 1998 Survey/reported WHO/UNICEF
97 1997 Survey/reported WHO/UNICEF
96 1996 Survey/reported WHO/UNICEF
93 1995 Survey/reported WHO/UNICEF
92 1994 Survey/reported WHO/UNICEF
92 1993 Survey/reported WHO/UNICEF
92 1992 Survey/reported WHO/UNICEF
Showing out of
Show more
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
1998
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
% of substance use disorder facilities offering hepatitis treatment
Few (1-10%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
0.68 (0.56 - 0.85) 2019 Modelled IHME
0.68 (0.56 - 0.84) 2018 Modelled IHME
0.68 (0.56 - 0.84) 2017 Modelled IHME
0.67 (0.55 - 0.83) 2016 Modelled IHME
0.66 (0.54 - 0.82) 2015 Modelled IHME
0.66 (0.54 - 0.82) 2014 Modelled IHME
0.66 (0.54 - 0.82) 2013 Modelled IHME
0.66 (0.54 - 0.82) 2012 Modelled IHME
0.66 (0.54 - 0.82) 2011 Modelled IHME
0.66 (0.54 - 0.82) 2010 Modelled IHME
0.66 (0.54 - 0.81) 2009 Modelled IHME
0.66 (0.54 - 0.81) 2008 Modelled IHME
0.66 (0.54 - 0.80) 2007 Modelled IHME
0.65 (0.53 - 0.80) 2006 Modelled IHME
0.65 (0.53 - 0.80) 2005 Modelled IHME
0.64 (0.52 - 0.79) 2004 Modelled IHME
0.63 (0.52 - 0.77) 2003 Modelled IHME
0.62 (0.51 - 0.75) 2002 Modelled IHME
0.61 (0.50 - 0.74) 2001 Modelled IHME
0.61 (0.50 - 0.74) 2000 Modelled IHME
0.6 (0.49 - 0.73) 1999 Modelled IHME
0.6 (0.49 - 0.73) 1998 Modelled IHME
0.6 (0.49 - 0.73) 1997 Modelled IHME
0.6 (0.49 - 0.73) 1996 Modelled IHME
0.59 (0.48 - 0.72) 1995 Modelled IHME
0.59 (0.48 - 0.72) 1994 Modelled IHME
0.59 (0.48 - 0.72) 1993 Modelled IHME
0.59 (0.48 - 0.72) 1992 Modelled IHME
0.59 (0.48 - 0.72) 1991 Modelled IHME
0.59 (0.47 - 0.72) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
2 (0.90 - 2) 2014 Modelled Gower et al, 2014
People who inject drugs (PWID)
Download
Value (%) Year Type Source
45.3 (38.10 - 52.60) 2010 Survey/reported Chatty A et al, 2010

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
46 (36 - 55) 2019 Modelled IHME
46 (36 - 56) 2018 Modelled IHME
46 (36 - 56) 2017 Modelled IHME
46 (36 - 56) 2016 Modelled IHME
46 (36 - 56) 2015 Modelled IHME
46 (36 - 56) 2014 Modelled IHME
46 (36 - 56) 2013 Modelled IHME
46 (36 - 56) 2012 Modelled IHME
46 (37 - 56) 2011 Modelled IHME
47 (36 - 56) 2010 Modelled IHME
46 (36 - 56) 2009 Modelled IHME
46 (36 - 56) 2008 Modelled IHME
46 (36 - 56) 2007 Modelled IHME
46 (36 - 56) 2006 Modelled IHME
46 (36 - 56) 2005 Modelled IHME
46 (36 - 56) 2004 Modelled IHME
46 (36 - 56) 2003 Modelled IHME
46 (36 - 56) 2002 Modelled IHME
46 (36 - 56) 2001 Modelled IHME
46 (36 - 56) 2000 Modelled IHME
46 (36 - 56) 1999 Modelled IHME
47 (36 - 56) 1998 Modelled IHME
47 (37 - 57) 1997 Modelled IHME
47 (36 - 57) 1996 Modelled IHME
47 (37 - 57) 1995 Modelled IHME
47 (37 - 57) 1994 Modelled IHME
47 (36 - 57) 1993 Modelled IHME
47 (36 - 57) 1992 Modelled IHME
47 (36 - 57) 1991 Modelled IHME
47 (36 - 57) 1990 Modelled IHME
Showing out of
Show more
Technical notes
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
1998
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
% of substance use disorder facilities offering hepatitis treatment
Few (1-10%)

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
0.53 (%)
2019
(0.43 - 0.62(%))
IHME
HCV (RNA/cAg+)
0.68 (%)
2019
(0.56 - 0.85(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
93
2019
(71 - 120)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
292
2019
(237 - 351)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.04 (%)
2019, latest modelled
(0.02 - 0.05(%))
IHME

Prevalence PWID

HCV
45.30 (%)
2010, survey/surveillance
(38.10 - 52.60(%))
Chatty A et al, 2010

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
95 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines